Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost added to minoxidil for androgenetic alopecia
IRCT20211228053553N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in androgenetic alopecia (AGA) comparing Minoxidil 5% with Latanoprost 0.005% + Minoxidil 5% (2 arms). Primary endpoints: Hair density and Severity of hair loss. Started Dec 2021; status: completed.
02
Drugs
latanoprostminoxidil
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on IRCT20211228053553N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211228053553N1.